BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-editing services, Pre-clinical pharmacology and efficacy evaluation, Animal models selling, Antibody devel… Read more
BIOCYTOGEN PHARMA. H YC1 (I54) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, BIOCYTOGEN PHARMA. H YC1 (I54) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BIOCYTOGEN PHARMA. H YC1 - Net Assets Trend (None–None)
This chart illustrates how BIOCYTOGEN PHARMA. H YC1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BIOCYTOGEN PHARMA. H YC1 (None–None)
The table below shows the annual net assets of BIOCYTOGEN PHARMA. H YC1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BIOCYTOGEN PHARMA. H YC1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BIOCYTOGEN PHARMA. H YC1 Competitors by Market Cap
The table below lists competitors of BIOCYTOGEN PHARMA. H YC1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Universal Insurance Holdings Inc
NYSE:UVE
|
$865.98 Million |
|
Radware Ltd
NASDAQ:RDWR
|
$866.10 Million |
|
Namsun Aluminium Co Ltd
KO:008355
|
$866.35 Million |
|
Shanghai Longcheer Technology Co., Ltd.
SHG:603341
|
$866.55 Million |
|
Yankershop Food Co Ltd
SHE:002847
|
$865.70 Million |
|
CNA FIN. DL 2,50
F:CNH
|
$865.20 Million |
|
Fujian Nebula Electronics Co Ltd
SHE:300648
|
$864.80 Million |
|
Jiangsu Yunyi Electric
SHE:300304
|
$864.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIOCYTOGEN PHARMA. H YC1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BIOCYTOGEN PHARMA. H YC1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BIOCYTOGEN PHARMA. H YC1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BIOCYTOGEN PHARMA. H YC1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIOCYTOGEN PHARMA. H YC1 (I54) | €- | N/A | N/A | $865.76 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |